
Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?
Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa.
Key insights include why New Zealand’s HTA model stands out as a global unicorn, how to navigate cultural and equity requirements in submissions, the importance of local evidence and stakeholder engagement, the impact of budget constraints and the shift toward real‑world data and outcome‑based reimbursement, and why the country may be the ideal testbed for innovations in AI, screening, and chronic care. Essential for professionals in pricing, market access, and global health policy.
Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!"
MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/
#MarketAccess #HealthEconomics #Pharma #Reimbursement #NewZealand #DigitalHealth #HTA #Pharmac #HealthcareInnovation #EquityInHealthcare #MAPPodcast #marketaccess #marketaccesspodcast
Mais episódios de "MAP - Market Access Podcast"



Não percas um episódio de “MAP - Market Access Podcast” e subscrevê-lo na aplicação GetPodcast.







